{
    "Trade/Device Name(s)": [
        "HYDRASHIFT 2/4 isatuximab"
    ],
    "Submitter Information": "Sebia",
    "510(k) Number": "K203184",
    "Predicate Device Reference 510(k) Number(s)": [
        "K960669"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CFF"
    ],
    "Summary Letter Date": "October 15, 2020",
    "Summary Letter Received Date": "October 27, 2020",
    "Submission Date": "November 9, 2021",
    "Regulation Number(s)": [
        "21CFR866.5510"
    ],
    "Regulation Name(s)": [
        "Immunoglobulins A, G, M, D, and E Immunological Test System"
    ],
    "Analyte Class(es)": [
        "immunology"
    ],
    "Analyte(s)": [
        "Monoclonal proteins",
        "IgG kappa",
        "IgG lambda",
        "IgA kappa",
        "IgA lambda",
        "IgM kappa",
        "IgM lambda",
        "Kappa free",
        "Lambda free",
        "Isatuximab IgG kappa"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "HYDRASYS 2 electrophoresis apparatus"
    ],
    "Method(s)/Technology(ies)": [
        "Immunofixation electrophoresis",
        "Agarose gel electrophoresis"
    ],
    "Methodologies": [
        "Immunofixation"
    ],
    "Submission Type(s)": [
        "Kit",
        "Reagent",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for HYDRASHIFT 2/4 isatuximab kit for qualitative detection of monoclonal proteins in serum by immunofixation electrophoresis",
    "Indications for Use Summary": "Qualitative detection of monoclonal proteins in human serum by immunofixation electrophoresis to enable visual evaluation in patients who have received isatuximab therapy",
    "fda_folder": "Immunology"
}